-
Mashup Score: 0Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® | Biogen - 5 day(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4News | Biogen - 6 day(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting | Biogen - 2 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 43Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP | Biogen - 2 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
We’ve received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for our treatment for amyotrophic lateral sclerosis (#ALS) in adults who have a specific gene mutation. Learn more about this news: https://t.co/BMl83MOB1e https://t.co/U2enSmz3Nb
-
-
Mashup Score: 1Events | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3News | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 21Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
We’re pleased to share that we’ve received approval from the European Commission for our #FriedreichsAtaxia (FA) therapy in people aged 16 years and older. This is the first treatment approved in the European Union for FA, a rare neurodegenerative disease: https://t.co/X8QfPwFyf0 https://t.co/GjeVraOVHL
-
-
Mashup Score: 21FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® | Biogen - 4 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 8FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA® | Biogen - 4 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, General HCPsTweet
We’re pleased to share that #Biogen received a positive CHMP opinion from #EMA for a proposed rheumatoid arthritis #biosimilar, based on a robust analytical, non-clinical and clinical data package comparing the product to the reference biologic. Read more: https://t.co/f45YA18bQk